Efficacy and safety comparison of different statins in elderly patients.
- Author:
Yahong CHEN
1
;
Chenggong JIANG
1
;
Meilin LIU
2
;
Fang LIU
1
;
Yan FAN
1
Author Information
- Publication Type:Clinical Trial
- MeSH: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin Calcium; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; drug therapy; Female; Fluorobenzenes; adverse effects; therapeutic use; Heptanoic Acids; adverse effects; therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; adverse effects; therapeutic use; Male; Middle Aged; Pyrimidines; adverse effects; therapeutic use; Pyrroles; adverse effects; therapeutic use; Rosuvastatin Calcium; Sulfonamides; adverse effects; therapeutic use
- From: Chinese Journal of Cardiology 2014;42(11):910-915
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy and safety of atorvastatin, rosuvastatin and xuezhikang capsule in elderly.
METHODSA total of 314 60-to-94-year-old (average (73.6 ± 7.9) years old) patients who were given different doses and types of statins were divided into three groups: the atorvastatin group (108 patients), the rosuvastatin group (104 patients) and the xuezhikang capsule group (102 patients). The serum TG, TC, LDL-C, HDL-C,ALT and CK were examined before and after the treatment which lasted for at least 4 weeks. All patients were divided into moderate risk group (13, 12 and 21 patients respectively in 3 groups); high risk group (40, 44 and 48 patients respectively in 3 groups) and very high risk group (55, 48 and 33 patients respectively in 3 groups ) according to guidelines on prevention and treatment of dyslipidemia in chinese adults (2007 version). The rate of reaching target goal and the dose when reaching target levels in different risk stratification groups were calculated and compared.
RESULTSSerum TC, LDL-C and non-HDL-C were significantly reduced after the 4-week-treatment in all the three groups (P < 0.01). Serum LDL-C level before and after treatment were (3.14 ± 0.78)mmol/L vs. (2.14 ± 0.65)mmol/L in atorvastatin group (the arevage dose was (16.4 ± 4.8)mg/d), (2.92 ± 0.77)mmol/L vs. (1.96 ± 0.55)mmol/L in rosuvastatin group (the arevage dose was (8.7 ± 3.0) mg/d), and (2.70 ± 0.62)mmol/L vs. (2.16 ± 0.61) mmol/L in xuezhikang capsule group (the arevage dose was (0.9 ± 0.3) g/d ). Among all the three groups of patients, the cases of reaching target levels of LDL-C were 13, 11 and 20 in patients at moderate risk, were 38(95.0%), 38(86.4%) and 40 (83.3%) in patients at high risk, and were 22(40.0%), 30(62.5%) and 17(51.5%) in patients at very high risk. There were no statistical differences in the rate of reaching target levels of LDL-C, non-HDL-C and TC in the three groups and at different risks (P > 0.05). One patient in the atorvastatin group showed ALT level elevation >3 times of the upper limit of normal value, there was no patient with CK level elevation >5 times of the upper limit of normal value.
CONCLUSIONAtorvastatin, rosuvastatin and xuezhikang capsule at low dose and/or standard dose are effective and safety in elderly patients.
